Mirari Márquez

Deciphering the role of complement system genes in pancreatic cancer susceptibility and prognosis

Alberto Langtry, Raúl Rabadán, Lola Alonso, Ioan Filip et autres

Pancreatic ductal adenocarcinoma (PDAC) genetic susceptibility is partially identified. The complement system (CS) influences carcinogenesis and participates in immunological defense and homeostasis; however, its role in PDAC genetic susceptibility and prognosis is underexplored. The association of SNPs within 111 CS-related genes with …

es, us, it, se, de, gb, ie (code pays fourni par la source)

Supplementary Material from Inflammatory-Related Genetic Variants in Non–Muscle-Invasive Bladder Cancer Prognosis: A Multimarker Bayesian Assessment

A. Masson-Lecomte, Evangelina López de Maturana, Michael E. Goddard, Antoni C. Picornell et autres

Supplementary methods, tables and figures

Supplementary Table S8 from Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study

Maria Frantzi, Kim E. van Kessel, Ellen C. Zwarthoff, Mirari Márquez et autres

Supplementary Table S8. Correlation analysis of the 116 peptide biomarkers with disease stage and grade and performance of peptide classifiers in detecting NMIBC and MIBC.

Supplementary Table S3 from Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study

Maria Frantzi, Kim E. van Kessel, Ellen C. Zwarthoff, Mirari Márquez et autres

Supplementary Table S3. Shortlist of significant biomarkers, as derived based on statistical analysis between primary UBC cases (n=341) and urological controls (n=110) - including negative after cystoscopy samples, samples from patients with hematuria and patients with benign urological diseases. Wilcoxon test was …

Supplementary Table S7 from Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study

Maria Frantzi, Kim E. van Kessel, Ellen C. Zwarthoff, Mirari Márquez et autres

Supplementary Table S7. Logistic regression analysis to investigate the potential confounding effect of previous supplementary treatment in the classification score of the 106 peptide biomarker panel.

Supplementary Table S5 from Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study

Maria Frantzi, Kim E. van Kessel, Ellen C. Zwarthoff, Mirari Márquez et autres

Supplementary Table S5. List of all peptides that were included in the peptide biomarker panels for detecting primary and recurrent UBC. For primary UBC, 116 peptide biomarkers were employed and optimized in an SVM-based classifier, using the discovery set of 451 urine …

Supplementary Table S2 from Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study

Maria Frantzi, Kim E. van Kessel, Ellen C. Zwarthoff, Mirari Márquez et autres

Supplementary Table S2. Clinical and demographical data for the urine samples (n= 636) from recurrent UBC patients, categorized in the discovery (n=425) and validation phase (n=211). The distribution of the patients which previously received additional treatment in the discovery and validation set …

Supplementary Table S1 from Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study

Maria Frantzi, Kim E. van Kessel, Ellen C. Zwarthoff, Mirari Márquez et autres

Supplementary Table S1. Clinical and demographical data for the full list of 721 samples from patients with primary UBC, separated in 451 urine samples to be included in the discovery phase and 270 urine samples to be included in the validation phase.

Supplementary Table S6 from Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study

Maria Frantzi, Kim E. van Kessel, Ellen C. Zwarthoff, Mirari Márquez et autres

Supplementary Table S6. Multivariate analysis for investigating the comparative performance of the biomarker classifier and cytology for detecting recurrence. Of the 211 subjects that were included in the validation phase, voided urinary cytology (VUC) results were available for 96 urinary samples.

Supplementary Table S4 from Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study

Maria Frantzi, Kim E. van Kessel, Ellen C. Zwarthoff, Mirari Márquez et autres

Supplementary Table S4. Table summarizing the significant biomarkers that were revealed after statistical analysis between recurrent UBC cases (n=109) and negative for recurrence controls (n=316), using Wilcoxon test. The significant biomarkers were subsequently compared for their trend of regulation among the different …

Data from Inflammatory-Related Genetic Variants in Non–Muscle-Invasive Bladder Cancer Prognosis: A Multimarker Bayesian Assessment

A. Masson-Lecomte, Evangelina López de Maturana, Michael E. Goddard, Antoni C. Picornell et autres

Abstract Background: Increasing evidence points to the role of tumor immunologic environment on urothelial bladder cancer prognosis. This effect might be partly dependent on the host genetic context. We evaluated the association of SNPs in inflammation-related genes with non–muscle-invasive bladder cancer (NMIBC) …

Data from Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study

Maria Frantzi, Kim E. van Kessel, Ellen C. Zwarthoff, Mirari Márquez et autres

Abstract Purpose: Urothelial bladder cancer presents high recurrence rates, mandating continuous monitoring via invasive cystoscopy. The development of noninvasive tests for disease diagnosis and surveillance remains an unmet clinical need. In this study, validation of two urine-based biomarker panels for detecting primary …